Reaction to The European Medicines Agency (EMA) and the European Commission latest publications

Reaction to The European Medicines Agency (EMA) and the European Commission publications of guidance to help pharmaceutical companies to prepare for the United Kingdom's withdrawal from the European Union.

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: “We have consistently stated that the existence of a single European regulatory system for medicines has generated considerable benefits for patients, the NHS and the industry. 

“We have urged both sides in the Brexit negotiations to find a way of maintaining these benefits in the interests of their citizens. It is concerning that the European Commission appears to be unwilling even to try to find a positive way forward in everyone’s interests rather than assuming the worst outcome before the negotiations even begin.”